newsfilter
← Latest News
GlobeNewswire·

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic clinical